• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
  • Contact Us
Multi-step screening of neoantigens’ HLA- and TCR-interfaces improves prediction of survival

Multi-step screening of neoantigens’ HLA- and TCR-interfaces improves prediction of survival

by Elena Iemma | May 13, 2021

Immunoinformatic Analysis of Pancreatic Cancer Mutanomes: Impact of Regulatory T Cell Neo-Epitopes on Patient Outcome

Immunoinformatic Analysis of Pancreatic Cancer Mutanomes: Impact of Regulatory T Cell Neo-Epitopes on Patient Outcome

by Annie De Groot | May 14, 2019

EpiVax_Oncology_NYAS_08May19_35Wx25H
Computational Identification of Self-Like Neoantigens Enables the Rapid Design of Immunogenic Cancer Vaccines

Computational Identification of Self-Like Neoantigens Enables the Rapid Design of Immunogenic Cancer Vaccines

by Annie De Groot | Apr 8, 2019

EpiVax_Oncology_TRI-CON_CT26_04Mar19_32w44h
Integrated Approaches for Design of Precision Cancer Immunotherapies: Selection of Class I and Class II T cell Neo-Epitopes and Removal Treg Epitopes

Integrated Approaches for Design of Precision Cancer Immunotherapies: Selection of Class I and Class II T cell Neo-Epitopes and Removal Treg Epitopes

by Annie De Groot | Mar 1, 2019

2018 Design of Cancer Immunotherapies – Selection of Neo-Epitopes, Removal of Tregitopes
From infectious disease to personalized cancer vaccines: Regulatory T cell epitopes determine patient outcomes and suppress neoantigen responses

From infectious disease to personalized cancer vaccines: Regulatory T cell epitopes determine patient outcomes and suppress neoantigen responses

by Annie De Groot | Nov 6, 2018

EpiVax_Oncology_Ancer_SITC_05Nov18_39Wx35H
« Older Entries

Recent Posts

  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • EpiVax Seminars in Tokyo
  • The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies
  • March of the Teenage B Cells
  • EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

Recent Comments

No comments to show.

Join our newsletter

 Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CSO, Dr. Annie De Groot. 

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline